Pharmaron 2026 H1 Revenue Up 17.92% to RMB 7.595 Billion, Net Profit Up 6.96%
Pharmaron reported 2026 first-half results with revenue of RMB 7.595 billion, up 17.92% year-on-year, and net profit attributable to shareholders of RMB 750 million, up 6.96%. Basic EPS was RMB 0.4138. The company expanded strategic clients, advanced its CDMO service pipeline to later stages, and new orders grew over 30% year-on-year.
Pharmaron disclosed its 2026 semi-annual report. During the reporting period, the company achieved total operating revenue of RMB 7.595 billion, up 17.92% year-on-year; net profit attributable to shareholders of the listed company was RMB 750 million, up 6.96%; basic earnings per share was RMB 0.4138.
In the first half, the company continued to expand strategic clients, its CDMO service project pipeline advanced to later stages, and new orders signed increased by more than 30% year-on-year.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceutical R&D Services, with intensity 60/100 and 80% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.